新型供受体游离DNA分离检测法在儿童实体器官移植中的应用
本研究开发了一种基于61个SNP组合的检测方法,无需供体基因分型即可定量儿童实体器官移植受者血浆中供体来源游离DNA(ddcfDNA)的比例。该方法在159例儿童肾、心、肺移植受者中验证,检测下限为0.25%,定量下限为0.5%(准确率84%),可在48小时内低成本出结果,但尚需大队列前瞻性研究证实其临床有效性。
要点
- 基于61个SNP的「无基因型」R法可无需供体基因分型定量ddcfDNA。
- 检测下限0.25%,定量下限0.5%时准确率84%。
- 已在159例儿童肾、心、肺移植受者中应用,82例有系列采样。
核心结论
- 开发并验证了一种无需供体基因分型即可定量儿童实体器官移植受者血浆ddcfDNA比例的新检测方法,可在48小时内低成本出结果。
- 该方法适用于相关与无关供受体对,但需大队列前瞻性研究证实临床有效性。
研究设计与样本
- 方法学开发与验证研究,采用61个SNP组合和自定义R脚本建模患者与供体基因型,仅需受者单样本。
- 用gDNA、cfDNA及可获得的供体样本验证性能;在159例儿童肾、心、肺移植受者中检测,其中82例有系列采样。
主要发现
- R「无基因型」法结果与已知供体基因型法相当,适用于相关与无关供受体对。
- 检测性能:空白限低于0.12%,检测限高于0.25%,定量限0.5%时准确率84%。
- 159例儿童实体器官移植受者无需供体基因分型即完成检测,82例获得系列样本。
关键数值与推荐
- 空白限低于0.12%,检测限高于0.25%,定量限0.5%时准确率84%。
- 采用61个SNP组合,仅需受者单样本,48小时内出结果。
临床怎么用
- 可用于儿童肾、心、肺移植受者ddcfDNA的无创监测,无需供体基因分型。
- 系列采样可用于动态监测,但临床有效性尚待前瞻性大队列验证。
局限性
- 儿童实体器官移植受者数据有限,需大队列前瞻性研究证实临床有效性。
- 检测限高于0.25%,定量限0.5%,对更低比例ddcfDNA的定量能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of cell-free DNA (cfDNA) as a noninvasive biomarker to detect allograft damage is expanding rapidly. However, quantifying the low fraction of donor-derived cfDNA (ddcfDNA) is challenging and requires a highly sensitive technique. ddcfDNA detection through unique donor single nucleotide polymorphisms (SNPs) is a recent new approach, however there are limited data in pediatric solid organ transplant (SOT) recipients. METHODS: We developed an assay using a combination of 61 SNPs to quantify the ddcfDNA accurately using a custom R script to model for both the patient and donor genotypes requiring only a single sample from the allograft recipient. Performance of the assay was validated using genomic DNA (gDNA), cfDNA and donor samples where available. RESULTS: The R "genotype-free" method gave results comparable to when using the known donor genotype. applicable to both related and unrelated pairs and can reliably measure ddcfDNA (limit of blank, below 0.12%; limit of detection, above 0.25%; limit of quantification 0.5% resulting in 84% accuracy). 159 pediatric SOT recipients (kidney, heart, and lung) were tested without the need for donor genotyping. Serial sampling was obtained from 82 patients. CONCLUSION: We have developed and validated a new assay to measure the fraction of ddcfDNA in the plasma of pediatric SOT recipients. Our method can be applicable in any donor-recipient pair without the need for donor genotyping and can provide results in 48 h at a low cost. Additional prospective studies are required to demonstrate its clinical validity in a large cohort of pediatric SOT recipients.
引用
- Preka E, Ellershaw D, Chandler N, et al. Cell-Free DNA in Pediatric Solid Organ Transplantation Using a New Detection Method of Separating Donor-Derived from Recipient Cell-Free DNA. Clin Chem. 2020. PMID: 32882007. doi:10.1093/clinchem/hvaa173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。